5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Zim Laboratories Ltd.

•
zimlab.inBSE: 541400NSE: ZIMLAB
Market Cap₹ 693 Cr.
Current Price
High / Low₹ 137 / 59
Stock P/E183.2
Book Value₹ 52
Price to Book1.13
Dividend Yield0.00 %
ROCE5.6 %
ROE2.3 %
Face Value₹ 10

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2014 • Pharmaceutical: 100.0%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 3.18x)
  • Company maintains a comfortable, low leverage position

CONS

  • A large part of profit comes from other income (135.6% of PBT)
  • Recent results are weak - TTM profit is down 45.3% versus prior year
  • Company has a low return on equity of 5.0% over last 3 years
  • Company has a low return on capital employed of 8.0%
  • Promoter holding has decreased over last 2 years: -2.9pp
  • Interest coverage is weak at 1.6x - earnings barely cover interest

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1899.8037.69455825.660.842901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9305.0084.45247018.510.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4913.0085.68186874.730.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1155.0025.53115211.690.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1395.9533.46112773.000.93785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1868.2592.32100943.830.11362.07123.942026.3129.1018.2031.50
7.LUPIN2105.0017.4196254.460.861416.9816.018276.8934.2828.8629.59
8.MANKIND2322.0546.9595911.140.04574.0929.124030.5912.8913.2426.30
9.DRREDDY1145.0029.6695570.850.70435.60-69.108099.80-5.2113.7510.63
10.AUROPHARMA1658.0025.7095397.650.241032.0325.229150.3517.4412.7620.54
11.GLENMARK2462.0038.6569483.710.10482.83927.884018.4831.3520.3520.03
12.ZIMLAB129.15187.50693.000.00-4.02-114.2494.1831.245.472.60
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
678596117829095109718810810393
627685102748184936782959699
Operating Profit59111588121546127-6
OPM %6.78%10.51%11.67%13.14%9.60%9.35%12.34%14.04%6.08%6.98%11.59%6.39%-6.89%
1112112212261
Interest2122333333334
Depreciation4444555555555
Profit before Tax-057111269-2065-5
Tax %36.36%23.30%31.10%26.94%30.56%34.59%27.86%37.34%25.88%47.83%28.16%27.43%28.53%
Net Profit-04581145-2043-4
-0.030.860.991.620.160.250.891.11-0.350.030.870.67-0.72

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
235272332274304329397365376370392
203238289255267292345325332341373
Operating Profit3234422037385140433019
OPM %13.43%12.49%12.79%7.21%12.12%11.51%12.91%10.97%11.52%7.98%4.80%
6925-356561111
Interest109111311867111314
Depreciation910111315151615201920
Profit before Tax182423-191936231885
Tax %-6.19%24.16%29.59%217.02%34.54%32.56%30.37%27.28%33.32%28.99%28.01%
Net Profit191816261325171264
EPS23.0311.289.861.073.462.675.133.442.411.11—
Dividend Payout %2.15%2.20%5.03%0.00%0.00%0.00%0.00%0.00%0.00%0.00%—

COMPOUNDED SALES GROWTH

10 Years:
3%
5 Years:
4%
3 Years:
-2%

COMPOUNDED PROFIT GROWTH

10 Years:
1%
5 Years:
1%
3 Years:
-38%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
1%
1 Year:
72%

RETURN ON EQUITY

10 Years:
8%
5 Years:
7%
3 Years:
5%
Last Year:
2%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2022

Dec 22

2:1

Quarterly Results & Bonus issue

2018

Oct 4

1:1

Bonus issue

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital881616161649494954
110127134135141154145183194230
818377908152609495105
Trade Payables45667266658259637277
692510143327545661
Total Liabilities250294324318318337341443466526
8994101111103103107160164160
Capital Work in Progress35855518244459
005888881318
35525556547554818694
00000001009492
Cash & Bank64338221137
117140153134140143152686466
Total Assets250294324318318337341443466526

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
35413826334742115148
Cash from Investing-7-26-23-19-6-14-35-72-41-57
Cash from Financing-25-10-15-2-26-33160-928
-01-100-01-1018

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
33.2633.2633.2633.2633.2633.2633.2630.3530.36
0.000.000.210.010.030.000.020.000.03
0.000.000.160.160.160.160.120.001.34
Government0.000.000.000.000.000.000.000.000.00
66.7366.7366.3766.5766.5466.5866.6069.6568.28

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-08-12
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-12 - Zim Laboratories Limited has informed the Exchange about Transcript

2026-08-12
Shareholders meeting

2026-08-12 - Zim Laboratories Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.

2026-08-08
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-08 - Zim Laboratories Limited has informed the Exchange about Link of Recording

2026-08-07
Copy of Newspaper Publication

2026-08-07 - Zim Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-06
General Updates

2026-08-06 - Zim Laboratories Limited has informed the Exchange about Earnings Presentation - Q1 FY27

2026-08-06
Outcome of Board Meeting

2026-08-06 - Zim Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

2026-08-04
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-04 - Zim Laboratories Limited has informed the Exchange about Schedule of meet

2026-07-30
Copy of Newspaper Publication

2026-07-30 - Zim Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-07-13
Allotment of Securities

2026-07-13 - Zim Laboratories Limited has informed the Exchange regarding allotment of 109451 securities pursuant to ESOP/ESPS at its meeting held on July 13, 2026

News

Recent coverage and analyst commentary for ZIMLAB

Loading news…

🤖

AI Stock Analyst

Zim Laboratories Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login